Liraglutide 5mg

About This Compound

Liraglutide is a 31-amino-acid peptide analog of human glucagon-like peptide-1, modified with a 16-carbon fatty acid side chain attached through a glutamic acid spacer. The way a heavier anchor holds a boat in place longer against a moving current, this fatty-acid modification is associated with binding to circulating plasma proteins, a structural design investigated for extending the peptide's presence in plasma relative to unmodified glucagon-like peptide-1.

Research Context

Madsen, Knudsen, Agersoe, Nielsen, Thøgersen, Wilken, and Johansen (J Med Chem 2007; PMID 17975905) reported a structure-activity series describing how fatty acid chain length, polarity, and bulkiness govern receptor potency and plasma protraction of glucagon-like peptide-1 fatty acid derivatives, including liraglutide, identifying fatty acid length as the parameter most closely tied to protraction. Plum, Jensen, and Kristensen (J Pharm Sci 2013; PMID 23853127) developed a reiterated stepwise equilibrium dialysis assay to quantify liraglutide's plasma protein binding, reporting greater than 98.9% binding at a clinically relevant concentration, with specific binding to human serum albumin measured at 99.4%. Pyke, Heller, Kirk, Ørskov, Reedtz-Runge, Kaastrup, Hvelplund, Bardram, Calatayud, and Knudsen (Endocrinology 2014; PMID 24467746) used a validated monoclonal antibody to map glucagon-like peptide-1 receptor localization across monkey and human tissue by immunohistochemistry, identifying receptor expression in pancreatic beta cells, vascular smooth muscle, cardiac sinoatrial node myocytes, and specific gastrointestinal cell populations.

Research Use Disclaimer

For Research Use Only. Not for human consumption.